Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


Press Releases
Company News
View Summary Stemline Therapeutics Prices $45 Million Public Offering of Common Stock
Jan 20, 2017
PDF 9.8 KB Add to Briefcase
View Summary Stemline Therapeutics Announces Proposed Public Offering of Common Stock
Jan 19, 2017
PDF 9.4 KB Add to Briefcase
View Summary Stemline Therapeutics Announces Date Change for the Company's Presentation at the 35th Annual J.P. Morgan Healthcare Conference
Jan 9, 2017
PDF 7.7 KB Add to Briefcase
View Summary Stemline Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Jan 9, 2017
PDF 7.7 KB Add to Briefcase
View Summary Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN
Jan 5, 2017
PDF 15.6 KB Add to Briefcase
View Summary Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH
Dec 6, 2016
PDF 12.1 KB Add to Briefcase
View Summary Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASH; High Response Rates Maintained Across All Lines
Dec 5, 2016
PDF 104.1 KB Add to Briefcase
View Summary Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend
Dec 2, 2016
PDF 51.8 KB Add to Briefcase
View Summary Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 21st Annual Meeting of the Society of Neuro-Oncology (SNO)
Nov 21, 2016
PDF 12.9 KB Add to Briefcase
View Summary Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress
Nov 8, 2016
PDF 15.9 KB Add to Briefcase
View Summary Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH Meeting
Nov 3, 2016
PDF 52.1 KB Add to Briefcase
View Summary Stemline Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 23, 2016
PDF 6.5 KB Add to Briefcase
View Summary Stemline Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Sep 7, 2016
PDF 7.3 KB Add to Briefcase
View Summary Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401
Aug 23, 2016
PDF 8.3 KB Add to Briefcase
View Summary Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
Aug 11, 2016
PDF 6.5 KB Add to Briefcase
View Summary Stemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress
Aug 4, 2016
PDF 21.5 KB Add to Briefcase
View Summary Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend
Jun 10, 2016
PDF 8.9 KB Add to Briefcase
View Summary Stemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend's Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO
Jun 6, 2016
PDF 7.8 KB Add to Briefcase
View Summary Stemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds
Jun 4, 2016
PDF 64.2 KB Add to Briefcase
View Summary Stemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow
Jun 3, 2016
PDF 8.6 KB Add to Briefcase
Showing 1-20 of 123 Page: 1 2 3 4 5 ... 7  Next 20
Add to Briefcase = add release to Briefcase


Copyright 2017 - Stemline Therapeutics, Inc. All rights reserved
Stemline